He provided an unprecedented vantage point, from inside the C-suite, onto the marketing of a prescription painkiller. An indictment or a lawsuit or a congressional report affords the view of a hostile outsider looking in. Rarely does an insider speak. When whistleblowers occasionally come forward, they usually come from the lower ranks, like Ray Furchak and Mia Guzman. They certainly aren’t the CEO. One reason that drug companies pay enormous sums to settle investigations before trial is to avoid a moment like this one—a former chief executive, under oath, describing how the business operates.
